Webinars >>FDA Regulations
3D Printing for Manufacturing Regulated Products: FDA’s Current Acceptance and Future Projections
3D printing offers the promise of easy and convenient custom manufacture of a variety of products. There have been several developments in the use of this technology to manufacture medical devices and even attempts to manufacture biologics and drugs. However, there is no clear direction from FDA regarding the approvability of products manufactured using 3D printing technology. There are some precedent regulatory paradigms available to understand what FDA may consider when regulating 3D printed products. This seminar will discuss practical strategic considerations when developing 3D printing technology for FDA-regulated products in the current regulatory environment and some tips on what to expect in the near and far future. Attendees will get an overview of applicable regulations and case studies to emphasize practical challenges and potential solutions for developing medical devices, biologics and drugs using this technology. GMP and QSR considerations for medical devices, biologics and drugs manufactured using 3D printing technology will be discussed.
Why should you attend:
The seminar will discuss the current available regulatory pathways to developing FDA-regulated 3D printed products and predictions on what to expect in the near future. Developers of 3D printing technology will benefit from the discussion on current available regulatory pathways for such products and what to expect in the future. 3D printing in personalized treatments will be discussed and attendees will be provided practical tips for pursuing approval with the FDA.
Areas Covered in the Session:
Who will benefit:
The following individuals or disciplines will benefit from attending this Webinar:
For additional information on the workshop agenda and logistics, please call 410-501-5777 or email: email@example.com